Invesco Markets p.Nasdaq Biotech UE A/  IE00BQ70R696  /

The objective of the Fund is to aim to track the Total Return performance of the NASDAQ Biotechnology Index (the "Index"), less fees, expenses and transaction costs. The Fund"s base currency is USD. The Index is designed to represent the performance of biotechnology and pharmaceutical securities on the NASDAQ Stock Market. The Index is a modified market capitalisation weighted index. The securities eligible for inclusion include common stocks, ordinary shares, ADRs and shares of beneficial interest or limited partnership interests. The Index has approximately 116 components and is rebalanced on a quarterly basis. Investors should note that the Index is the intellectual property of the index provider. The Fund is a passively managed Exchange-Traded Fund. To achieve the objective the Fund will use unfunded swaps ("Swaps"). These Swaps are an agreement between the Fund and an approved counterparty to exchange one stream of cash flows against another stream but do not require the Fund to provide collateral, on the basis that the Fund has already invested in a basket of equities and equity related securities (namely shares). Please note that the Fund will purchase securities that are not contained in the Index. The performance of the Index is swapped from the counterparty to the Fund in exchange for the performance of equities and equity related securities held by the Fund.

The objective of the Fund is to aim to track the Total Return performance of the NASDAQ Biotechnology Index (the "Index"), less fees, expenses and transaction costs. The Fund"s base currency is USD. The Index is designed to represent the performance of biotechnology and pharmaceutical securities on the NASDAQ Stock Market. The Index is a modified market capitalisation weighted index. The securities eligible for inclusion include common stocks, ordinary shares, ADRs and shares of beneficial interest or limited partnership interests. The Index has approximately 116 components and is rebalanced on a quarterly basis. Investors should note that the Index is the intellectual property of the index provider.